Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART101 after HLA-mismatched peripheral blood stem cell transplantation with post-transplant cyclophosphamide
2024-517953-28-00Phase 2Authorised
- Sponsor
- Smart Immune
- Start
- Nov 2024
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of SMART101 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more (2 arms), sponsored by Smart Immune. Primary endpoints: Safety - Unexpected Unacceptable Toxicities (UUT) and Efficacy - T-cell reconstitution rate. Planned start Nov 2024; status: authorised.
02
Drugs
SMART101
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-517953-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517953-28-00.